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Targeted therapy of cancer is often associated with clinically significant diarrhoea; however, the mechanisms underpinning this
adverse effect are currently unknown. Diarrhoea following treatment with tyrosine kinase inhibitors (TKIs) of EGFR is particularly
troublesome. Until recently, understanding of EGFR TKI-induced diarrhoea has been limited to clinical observation. However, our
group has recently developed the first ratmodel of EGFRTKI-induced diarrhoea.This paper reviews the published and unpublished
findings.
1. Introduction
Molecularly targeted cancer agents are emerging as an
effective approach to the treatment of a range of different
tumours. They have ushered in a new age of personalised
medicine in cancer therapy and have been made possible
due to significant advances in genetics andmolecular biology
in the last two decades. However, despite improved speci-
ficity for cancerous cells compared to traditional cytotoxic
chemotherapy, these agents are still associated with a number
of important clinical adverse effects, particularly rash and
diarrhoea. Importantly, the mechanisms underlying these
toxicities and the significance to patient outcomes are poorly
understood and have received little attention to date. In
response to this gap in knowledge, our research group has
developed a clinically relevant rat model of diarrhoea in
response to treatmentwith the smallmolecule tyrosine kinase
inhibitor (TKI) of epidermal growth factor receptor (EGFR)
and human epidermal growth factor receptor (HER2), lapa-
tinib. This review will reflect on the rationale for embarking
on the project, the series of experiments that established the
model, and the challenges encountered along the way.
2. The Importance of Diarrhoea as an Adverse
Effect of Targeted Cancer Therapy
Diarrhoea is a troublesome side effect of almost all systemic
cancer treatments and has been researched intensely [1–3].
Whilst there is improved understanding of the pathobiology
of diarrhoea following traditional chemotherapy agents, the
same is not true for targeted cancer agents. The reasons
are multifactorial and include targeted therapies being a
relatively recent addition to the arsenal of cancer therapies,
the speed at which these new drugs emerge, and the diversity
of targets for each agent. There are a number of different
classes of targeted therapy agents, with arguably the most
established being the small molecule inhibitors of receptor
tyrosine kinases (TKIs). General subclasses of TKIs have been
based on the specific molecules targeted, including EGFR,
VEGFR, and PDGFR to name a few, although in reality most
agents are multitargeted and selectively promiscuous for off-
target kinases [4]. This creates significant complexity when
elucidating mechanisms of adverse effects due to TKIs. What
is more, TKIs may be administered alone or in combination
with conventional chemotherapy agents or radiotherapy.
These multimodal regimens may compound or act syner-
gistically on normal tissue damage, making it difficult to
separate the role of TKIs on injury and, consequently,manage
resulting symptoms.
Diarrhoea is one of the most common adverse events
recorded following treatment with all TKIs and is a dose
limiting toxicity for TKIs that block EGFR signalling [5].
Diarrhoea is an important cause of therapy interruption
and negatively affects compliance [6]. Diarrhoea theoreti-
cally may also impede full dosage of orally administered
agents [7], although any influence on pharmacokinetics and
pharmacodynamics has yet to be investigated. In patients
treated with TKIs targeting EGFR, diarrhoea is an important
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Table 1: Diarrhoea associated with FDA approved TKIs targeting EGFR.
Drug Target All grade diarrhoea Grade 3/4 diarrhoea Reference
Erlotinib (Tarceva) EGFR 62–76% 3–10% [8]
Gefitinib (Iressa) EGFR 57–67% 12–13% [8]
Lapatinib (Tykerb) EGFR, HER2 50% 6% [12]
Vandetanib (Caprelsa) EGFR, VEGFR 56–67% 10% [13, 14]
Afatinib (Gilotrif) EGFR, HER2, and ErbB4 78% 14% [8]
clinical toxicity which is worsened when combined with
chemotherapy. In phase III trials of EGFR TKIs, gefitinib,
and erlotinib, diarrhoea was found second only to rash as
the most commonly reported adverse event [8]. In a recent
meta-analysis of multiple EGFR TKIs and nonsmall cell lung
cancer (NSCLC), it was found that severe grade diarrhoea
was increased significantly by addition of chemotherapy [9].
In a meta-analysis of phase II studies of EGFR TKIs in head
and neck squamous cell carcinoma (HNSCC), diarrhoea
occurred in 45% of patients. Interestingly, diarrhoea was also
associated with clinical benefit defined as complete response,
partial response, or stable disease (OR = 1.77, 95% CI = 1.05–
2.97) and overall survival (HR = 0.65, 95% CI = 0.51–0.83)
[10]. Associations between diarrhoea and treatment response
require further investigation, although it is plausible given
the established link between rash and response to EGFR
inhibition [11].
A summary of diarrhoea associated with TKIs for EGFR
is shown in Table 1.
3. What Is Known about
TKI-Induced Diarrhoea?
Despite diarrhoea being extremely common and in some
cases dose-limiting, there has been almost no clinical
research investigating the underlying causes of this side
effect. Possible reasons may include the misconception that
diarrhoea is an unimportant toxicity combined with the
difficulties in directly assessing the gastrointestinal tract.
Although there is yet to be any defined pathogenesis, some
authors cautiously speculate that TKI-induced diarrhoea
is a specific toxicity separate from chemotherapy-induced
mucosal injury [15], which arises from lesions within the
small intestine [16]. In the instance of TKI monotherapy,
studies have shown that diarrhoea is dose dependent rather
than associated with pharmacokinetics [17, 18], suggesting
that the toxicity is predominantly caused by luminal exposure
to the drug.
EGFR is expressed by cells of epithelial origin, including
the skin and gastrointestinal tract, so it is not surprising that
toxicities affect these systems. The prevailing hypothesis is
that inhibition of EGFR signallingwill lead to reduced growth
and healing of the intestinal epithelium, leading to mucosal
atrophy, due to the stimulatory effect of the EGFR pathway on
enterocyte proliferation [19]. An alternative theory implicates
excess chloride secretion caused by altered EGFR signalling
to downstream pathways and channels [20].This is emerging
as a favoured explanation due to the known inhibitory
effects of EGF on chloride secretion in the intestine and
the understanding of the profound importance of chloride
movement in secretory diarrhoea [21].
Diarrhoea is often worsened during TKI and chemother-
apy combination treatment and may be due to shared
metabolic and drug efflux pathways between drugs. For
example, coadministration of lapatinib and paclitaxel results
in 20% increased exposure to both agents, suggested to
be through downregulation of CYP3A4 [22]. Pazopanib
downregulates UGT1A1, so use with drugs that are substrates
for the enzyme, such as irinotecan, may increase toxicity [23].
Both TKIs and chemotherapy agents are substrates for the
drug efflux transporters of the ATP Binding Cassette family
and each has the potential to inhibit clearance of the other
drug, leading to drug accumulation, an important cause of
increased toxicity [24]. When TKIs are combined with radio-
therapy, there may be reduced tissue healing by inhibition
of growth factors in response to radiation, in addition to
enhanced apoptosis. These are all plausible explanations but
have yet to be proven given that there is no direct research
completed to date.
Recognising and understanding this major lack of
research, we decided to establish a platform to investigate
mechanisms and test interventions for EGFR TKI-induced
diarrhoea which led to the development the first rat model
of targeted therapy-induced diarrhoea.
4. Development of a Model to
Study TKI-Induced Diarrhoea
The use of animal models to investigate treatment-related
toxicity has provided a wealth of knowledge in regard to
injury pathogenesis and has enabled relatively high through-
put testing of interventions matched to pathobiology, which
has been particularly evident in the mucositis field [25–27].
In contrast, there is a paucity of models available to
specifically investigate mechanisms of TKI-induced diar-
rhoea. As such, our group has developed a rat model of
targeted therapy-induced diarrhoea that uses a four-week
schedule of daily oral lapatinib treatment to induce mild
to moderate diarrhoea, whilst achieving a Cmin similar to
clinical studies. Conventionally housed male albino Wistar
rats received an oral gavage of study drug (TKI) or vehicle
(0.5% methylcellulose/0.1% Tween 80) every 24 h for 28
days. Daily measurements of weight loss, diarrhoea, and
distress were recorded. Groups of rats were sacrificed each
week to assess circulating lapatinib levels and gastrointestinal
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tissue changes at the morphological and molecular level. Full
experimental details can be found in Bowen et al. [28].
Lapatinib (GW572016/Tykerb GlaxoSmithKline) was
chosen as the initial TKI for testing in the model since it is
a highly promising drug in clinical trials for the treatment
of multiple solid tumours [22], but optimal use is limited by
diarrhoea. Lapatinib is an orally administered small molecule
TKI targeting ErbB-1 (EGFR) and ErbB-2 (HER2) [29].
Lapatinib’s anticancer effect is mediated through inhibition
of HER2 in overexpressing tumours, preventing downstream
signalling to extracellular signal-related kinase- (ERK-) 1/2
and phosphatidylinositol-3󸀠-kinase (PI3K)/Akt pathways.
ERK and PI3K have numerous roles within the cell pri-
marily concerning growth, proliferation, and survival [30].
Lapatinib was first approved for treatment of HER2 posi-
tive advanced and metastatic breast cancer in combination
with capecitabine in patients who have previously received
anthracycline, taxane, and trastuzumab [31]. Lapatinib is
now also approved for treatment of postmenopausal women
with hormone receptor positive metastatic breast cancer
that overexpress HER2 and for whom hormonal therapy
is indicated. Diarrhoea is the most common adverse event
associated with lapatinib [32]. A pooled analysis of phases II
and III studies of lapatinib showed that 51% of patients expe-
rience diarrhoea [12]. Addition of lapatinib to capecitabine
increased diarrhoea from 30% to 65%, whilst addition of
lapatinib to paclitaxel increased diarrhoea from 28% to 48%.
Not only was diarrhoea incidence and severity increased, but
also it occurred with earlier onset to chemotherapy alone
and was the most common cause of dose reduction. In the
recent NeoALLTO trial, 23% of patients receiving lapatinib
combined with paclitaxel before definitive surgery experi-
enced severe grade diarrhoea [33]. No significant association
was observed between diarrhoea and pathologic complete
response [34]. As such, diarrhoea is an important cause of
poor treatment outcomes.
In our rat model, we found that lapatinib in a dose range
of 100 to 500mg/kg induced diarrhoea in a majority of rats,
without being excessively toxic over the month of treatment.
At 240mg/kg lapatinib, roughly 70% of rats experienced diar-
rhoea during the treatment period, with diarrhoea episodes
characterised by intermittent and repeated presentation [28].
This reflects what is seen clinically and uniquely positions
the model for investigation of interventions. Furthermore,
circulating lapatinib concentrations remained at a clinically
relevant [16, 35] steady state throughout the treatment period
(Figure 1). Pharmacokinetic studies have consistently found
that lapatinib exposure varies considerably between patients
[36], which was also noted in our rat study.The causes for this
variability are currently unknown but may be influenced by
the presence of food in the stomach which has been shown
to increase bioavailability of lapatinib [36]. In our study, rats
were not fasted before or after administration of lapatinib
which may have contributed to the observed variation in
steady state levels.
Although ourmodel created symptomology similar to the
clinical situation, somewhat surprisingly there was nomacro-
scopic or microscopic tissue injury seen within the jejunum
or colon. As such, lapatinib does not cause epithelial atrophy
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Figure 1: Circulating lapatinib measured weekly. Data shown is
median with range, 𝑛 = 12. Steady state lapatinib levels were
determined by LC/MS/MS and remained similar across the four
weeks of treatment (𝑃 > 0.05, one-way ANOVA).
at clinically relevant doses in the rat, and the mechanism of
diarrhoea does not rely on this change occurring. In contrast
to these findings, studies in mice examining various EGFR
TKIs have shown gastrointestinal damage with significant
epithelial atrophy. Mice administered gefitinib twice daily
for ten days had prominent changes in the small intestine
[37]. The authors concluded that the appearance of the small
intestine was consistent with necrotic enterocolitis due to
inhibited intestinal homeostasis and healing. A study that
treated mice for nine days with the pan-ErbB inhibitor,
canertinib, showed that treatment resulted in decreased villus
height and small intestinal wet weight [38]. Lastly, erlotinib,
administered as an intraperitoneal injection daily for ten
days, caused reduced small intestinal weight and villus height,
and this was worsened when given in combination with
cisplatin [39]. In each model, cotreatment with GLP-2 or
other growth factors including KGF or EGF could reverse
the atrophy caused by EGFR TKIs. It is unclear whether
the dose and schedule selected in these studies recapitulated
the clinical effects of diarrhoea and if circulating levels of
the drugs were within a human equivalent range. However,
it does uncover the potential issue of species differences in
response to TKIs between mice and rats.
5. Addition of Chemotherapy to the Model of
TKI-Induced Diarrhoea
Our rat model of TKI-induced diarrhoea also assessed the
effect of combination therapy with paclitaxel due to clinically
important diarrhoea seen in patients treated with both
lapatinib and chemotherapy. Paclitaxel was chosen as the
chemotherapy agent to investigate in our model since it is the
current drug of choice for neoadjuvant breast cancer therapy
[33]. Paclitaxel (Taxol) is a microtubule stabilisation agent
of the taxane class and is considered moderately mycotoxic
[40]. We found that combined treatment with paclitaxel and
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Figure 2: Diarrhoea incidence and severity. Data shown is pro-
portion of rats that experienced diarrhoea at each severity level
measured over the duration of treatment, 𝑛 = 30. Addition of
paclitaxel to lapatinib treatment caused a significant increase in the
proportion of rats that experienced severe grade diarrhoea (𝑃 <
0.001, chi-square test).
rats with severe diarrhoea (Figure 2) and also caused weight
loss indicating clinically important intestinal injury in our
model. Furthermore, combined lapatinib and paclitaxel treat-
ment resulted in increased circulating lapatinib levels, which
again reflects what is seen clinically [22]. Although the impact
of paclitaxel treatment is likely the main contributor to
increased gastrointestinal toxicity, we are unable to discount
the role of absorbed lapatinib on diarrhoea entirely. Although
most investigators suggest that unabsorbed drug is the cause
of lapatinib-induced diarrhoea, clinical studies of erlotinib
have shown an association between circulating drug levels
and toxicity [41, 42]. Further investigation is needed to assess
changes in drug exposure following concurrent treatment
regimens and the effect on diarrhoea.
Given that we found no measurable intestinal pathol-
ogy following lapatinib treatment alone, our study did not
support the theory of TKI-induced direct mucosal damage
leading to diarrhoea [15]. It is well established that treatment
with conventional chemotherapy drugs causes atrophy of
intestinal mucosa leading to mixed secretory/osmotic-type
diarrhoea due to an inability to control solute absorption and
secretion through decreased surface area [2]. It is clear that
lapatinib-induced diarrhoea is occurring through a differ-
ent mechanism. The alternative hypothesis is that lapatinib
alters chloride secretion into the gastrointestinal lumen by
interfering with inhibitory signals mediated through EGFR
[15]. Our study does not support this either since blood
biochemical analysis found that 240mg/kg lapatinib had no
significant effect on serum chloride. As such, the role of
chloride secretion, or other ion transport mechanisms in
lapatinib-induced diarrhoea, still remains unclear.
In contrast, combined lapatinib and paclitaxel treatment
did cause gut tissue alterations, including epithelial apoptosis,
crypt hyperplasia, and inflammatory infiltrate to the lamina
propria. Previous research by our group using conventional
chemotherapy drugs including methotrexate, 5-fluorouracil,
and irinotecan has shown that apoptosis is a key early marker
of chemotherapy-induced gastrointestinal injury, and crypt
hyperplasia occurs during the regenerative phase following
severe injury [26, 43–46]. Our rat models of diarrhoea due
to acute chemotherapy treatment and the similarities in
marker profiles in the current model provide evidence that
paclitaxel combined with lapatinib caused intestinal injury,
albeit relatively mild severity. Of particular interest is the
chemosensitzing effect of lapatinib to paclitaxel on the small
intestine. Our study found no effect of paclitaxel alone or
lapatinib alone on small intestinal weight, crypt hyperplasia,
or apoptosis, whereas combined treatment increased each of
these outcomes significantly [28]. It should also be noted that
changes in these parameters in the large intestine were not
observed following lapatinib with or without paclitaxel. This
supports the suggestion that lapatinib-induced diarrhoea
seen in clinical trials is caused by damage localised to the
small intestine [16] and indicates that this should be the
focus of intervention studies. The more pronounced effects
on the small intestine relative to the colon are likely a factor
of greater exposure of the mucosal surface to unabsorbed
drug in the proximal intestine. Furthermore, the relatively
higher rate of epithelial turnover also increases susceptibility
of the small intestine to the cytostatic and cytotoxic effects of
conventional chemotherapy agents.
6. Future Directions
Development of this model is the first step in creation of a
clinically relevant platform to examine mechanisms and test
treatments for EGFR TKI-induced diarrhoea. We have built
upon our group’s collection of established chemotherapy-
induced models of diarrhoea and believe this is a significant
addition to the field. However, our preliminary findings have
identified a number of aspects that need further clarification
to improve our understanding andmanagement of lapatinib-
induced diarrhoea. Firstly, given that lapatinib bioavailability
is relatively low and highly variable between patients [36],
a close examination of factors that regulate gastrointestinal
absorption is needed. This should include the pharmacoki-
netic effect of coadministration of antimotility agents used to
manage diarrhoea. This research will improve dose tailoring
for individuals, leading to improved drug safety and efficacy.
Secondly, to further increase the utility of the model it should
be isogenic and tumour bearing. This will allow evaluation
of interventions for lapatinib-induced diarrhoea in rats that
are not immunologically altered, whilst ensuring that there
is no tumour protection. Finally, future research should
concentrate on expanding the number of agents used in
combination with lapatinib in this model. To date we have
only assessed lapatinib together with a single chemotherapy
drug. However, EGFR inhibition alongside radiation therapy
is a proven clinical approach to head and neck cancer [47]. As
such, this model could be adapted for localised radiotherapy,
multiagent chemotherapy, or any combination thereof, with
lapatinib.
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The outlook for the clinical use of TKIs is to increasingly
include them in first line treatment of curable disease.
Therefore, it is extremely important to have a thorough
understanding of the adverse effects associated with their use
and the best approaches to minimise toxicity. Animal models
such as the one described herein are an invaluable source of
knowledge and will provide the platform to conduct studies
that improve our knowledge of the mechanisms underlying
diarrhoea as well as to uncover the best intervention targets.
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